scholarly journals Weighing the waitlist: Weight changes and access to kidney transplantation among obese candidates

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0242784
Author(s):  
Elaine Ku ◽  
Adrian M. Whelan ◽  
Charles E. McCulloch ◽  
Brian Lee ◽  
Claus U. Niemann ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Weight Loss ◽  
Kidney Transplantation ◽  
Weight Gain ◽  
Body Mass ◽  
Deceased Donor ◽  
Weight Changes ◽  
Living Donor Transplantation ◽  
Race Ethnicity ◽  
End Stage

High body mass index is a known barrier to access to kidney transplantation in patients with end-stage kidney disease. The extent to which weight and weight changes affect access to transplantation among obese candidates differentially by race/ethnicity has received little attention. We included 10 221 obese patients waitlisted for kidney transplantation prior to end-stage kidney disease onset between 1995–2015. We used multinomial logistic regression models to examine the association between race/ethnicity and annualized change in body mass index (defined as stable [-2 to 2 kg/m2/year], loss [>2 kg/m2/year] or gain [>2 kg/m2/year]). We then used Fine-Gray models to examine the association between weight changes and access to living or deceased donor transplantation by race/ethnicity, accounting for the competing risk of death. Overall, 29% of the cohort lost weight and 7% gained weight; 46% received a transplant. Non-Hispanic blacks had a 24% (95% CI 1.12–1.38) higher odds of weight loss and 22% lower odds of weight gain (95% CI 0.64–0.95) compared with non-Hispanic whites. Hispanics did not differ from whites in their odds of weight loss or weight gain. Overall, weight gain was associated with lower access to transplantation (HR 0.88 [95% CI 0.79–0.99]) compared with maintenance of stable weight, but weight loss was not associated with better access to transplantation (HR 0.96 [95% CI 0.90–1.02]), although this relation differed by baseline body mass index and for recipients of living versus deceased donor organs. For example, weight loss was associated with improved access to living donor transplantation (HR 1.24 [95% CI 1.07–1.44]) in whites but not in blacks or Hispanics. In a cohort of obese patients waitlisted before dialysis, blacks were more likely to lose weight and less likely to gain weight compared with whites. Weight loss was only associated with improved access to living donor transplantation among whites. Further studies are needed to understand the reasons for the observed associations.

scholarly journals Modification in body weight associated with antiepileptic drugs

2010 ◽  
Vol 68 (2) ◽  
pp. 277-281 ◽  
Author(s):  
Camilla N. De Gaspari ◽  
Carlos A.M. Guerreiro
Keyword(s):  
Physical Activity ◽  
Body Mass Index ◽  
Body Weight ◽  
Weight Gain ◽  
Antiepileptic Drugs ◽  
Body Mass ◽  
Dietary Habits ◽  
Weight Changes ◽  
Body Weight Changes ◽  
Epileptic Patients

Antiepileptic drugs (AED) may cause body weight changes. OBJECTIVE: To evaluate the dietary habits and body weight associated with AED in epileptic patients. METHOD: Sixty-six patients were subjected to two interviews, and had their weight and body mass index calculated and compared at both times, interval between six to eight months. RESULTS: It was observed that 59.1% showed weight gain. The patients who had no weight gain had a greater proportion of individuals who engaged in some form of physical activity. However, of the 45 patients who maintained their initial dietary and medication pattern, 75.6% recorded a weight gain. Weight gain was seen in 66.7% of patients on carbamazepine (n=18), 60% on valproate (n=5), 50% on carbamazepine+clobazam treatment (n=14), and 58.3% of patients on other(s) polytherapy (n=12). CONCLUSION: The patient should be alerted to possible weight gain, and should be advised about dieting and participating in regular physical activity.

scholarly journals Work stress, weight gain and weight loss: evidence for bidirectional effects of job strain on body mass index in the Whitehall II study

2006 ◽  
Vol 30 (6) ◽  
pp. 982-987 ◽  
Author(s):  
M Kivimäki ◽  
J Head ◽  
J E Ferrie ◽  
M J Shipley ◽  
E Brunner ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Weight Loss ◽  
Weight Gain ◽  
Body Mass ◽  
Work Stress ◽  
Job Strain ◽  
Bidirectional Effects

scholarly journals A dedicated nurse-led service for antipsychotic-induced weight gain

2004 ◽  
Vol 28 (5) ◽  
pp. 164-166 ◽  
Author(s):  
Ruth I. Ohlsen ◽  
Janet Treasure ◽  
Lyn S. Pilowsky
Keyword(s):  
Body Mass Index ◽  
Weight Loss ◽  
Weight Gain ◽  
Motivational Interviewing ◽  
Body Mass ◽  
Weight Change ◽  
Psychosocial Intervention ◽  
Clinical Implications ◽  
Prevention Strategies ◽  
Weight Monitoring

Aims and MethodTo evaluate a psychosocial intervention for patients treated with antipsychotics with body mass index (BMI) > 25. A total of 44 patients (mean age (s.e.) 37.6 (1.2); 28 female, 16 male) received dietary and exercise advice with motivational interviewing. Weight and BMI were measured at baseline and monthly thereafter. Patients were offered weight monitoring for 1 year.ResultsOverall mean weight loss was 3.1 kg (mean 3.22%). Modal (range) weight change was 74.2 (719.2 kg to +8.7 kg).Clinical ImplicationsOverall weight loss was not significant after 355.7 (32.5) (mean, s.e.) days. Determinants of response remain unclear. Avoiding weight gain in the first instance is critical. Further research will explore determinants of antipsychotic-induced weight gain and prevention strategies.

scholarly journals Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study

2002 ◽  
Vol 57 (3) ◽  
pp. 98-102 ◽  
Author(s):  
Alfredo Halpern ◽  
Claudia Cozer Leite ◽  
Nathan Herszkowicz ◽  
Alfonso Barbato ◽  
Ana Paula Arruda Costa
Keyword(s):  
Blood Pressure ◽  
Body Mass Index ◽  
Weight Loss ◽  
Placebo Group ◽  
Weight Gain ◽  
Side Effects ◽  
Body Mass ◽  
Obese Patients ◽  
Double Blind ◽  
Discontinuation Of Treatment

This is a double-blind, placebo-controlled study of the efficacy, safety, and tolerability of sibutramine in the management of obese patients for a 6-month period. METHOD: Sixty-one obese patients (BMI >30, <40 kg/m2), aged 18-65 years were evaluated. In the first phase of the study (30 days), the patients were given a placebo. We monitored compliance with a low-calorie diet (1200 kcal/day) and to the placebo. In the next stage, the double-blind phase (6 months), we compared placebo and sibutramine (10 mg/day). The criteria for evaluating efficacy were weight loss, reduction in body mass index (BMI), and abdominal and hip circumferences. Tolerability was assessed based on reported side effects, variation in arterial blood pressure and heart rate, metabolic profile (fasting glucose, total cholesterol and its fractions, and triglycerides), laboratory tests (renal and hepatic functions), and flow Doppler echocardiogram. RESULTS: We observed a greater weight loss (7.3 kg, 8% vs 2.6 kg, 2.8%) and a reduction in body mass index (7.4% vs 2.1%) in the sibutramine group than in the placebo group. Classifying the patients into 4 subgroups according to weight loss (weight gain, loss <5%, loss of 5% to 9.9%, and loss >10%), we observed a weight loss of >5% in 40% of the patients on sibutramine compared with 12.9% in the placebo group. We also detected weight gain in 45.2% of the placebo group compared to 20% in the sibutramine group. The sibutramine group showed improvement in HDL- cholesterol values (increased by 17%) and triglyceride values (decreased by 12.8%). This group also showed an increase in systolic blood pressure (6.7%, 5 mmHg). There were no changes in echocardiograms comparing the beginning and end of follow-up, and side effects did not lead to discontinuation of treatment. DISCUSSION: Sibutramine proved to be effective for weight loss providing an 8% loss of the initial weight. Compliance to prolonged treatment was good, and side effects did not result in discontinuation of treatment. These data confirmed the good efficacy, tolerability, and safety profiles of sibutramine for treatment of obesity.

scholarly journals Characterization of Body Composition and Fat Mass Distribution 1 Year After Kidney Transplantation

2016 ◽  
Vol 27 (1) ◽  
pp. 10-15 ◽  
Author(s):  
Catherine Pantik ◽  
Young-Eun Cho ◽  
Donna Hathaway ◽  
Elizabeth Tolley ◽  
Ann Cashion
Keyword(s):  
Body Mass Index ◽  
Body Weight ◽  
Kidney Transplantation ◽  
Weight Gain ◽  
Body Mass ◽  
Body Fat ◽  
Fat Mass ◽  
Body Fat Mass ◽  
Total Body Fat ◽  
Total Body

Purpose: In some recipients, significant weight gain occurs after kidney transplantation. Weight gain is associated with poor outcomes, particularly increased cardiovascular risk. In this study, we characterized changes in body mass index and body fat mass and compared them based on gender and race. Methods: Fifty-two kidney transplant recipients (aged ≥18 years old, 50% men, 58% African American) were enrolled into a prospective study. Body mass index and body fat mass were measured at baseline and 12 months posttransplant. Body fat mass was determined by dual-energy X-ray absorptiometry. Results: The mean increase in body weight was 3.7kg at 12 months; 36.5% (n=19) gained at least 10% of their baseline body weight. Body mass index, percentage of total body fat, and trunk fat were significantly increased. In subgroups, women and African American showed significant increases in body mass index and body fat measures. More participants were classified as obese based on total body fat compared to body mass index. Calories from fat were significantly increased at 12 months and associated with increased body mass index, total body fat, and trunk fat. Days of physical activity were significantly increased. Conclusion: Both body mass index and total body fat mass were significantly increased at 12 months following kidney transplantation, especially for women and African Americans. Importantly, more participants were classified as obese based on total body fat compared to body mass index. Relevant nutrition and physical intervention should be provided, and both body mass index and body fat mass should be evaluated when monitoring weight gain.

Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group

2021 ◽  
pp. 095646242098369
Author(s):  
Michał Łomiak ◽  
Jan Stępnicki ◽  
Tomasz Mikuła ◽  
Alicja Wiercińska-Drapało
Keyword(s):  
Body Mass Index ◽  
Body Weight ◽  
Weight Gain ◽  
Antiretroviral Therapy ◽  
Body Mass ◽  
Tenofovir Disoproxil Fumarate ◽  
Weight Changes ◽  
Mineral Density ◽  
Significant Weight Gain ◽  
Tenofovir Alafenamide

Tenofovir alafenamide fumarate (TAF) is an alternative to tenofovir disoproxil fumarate (TDF). Currently, TAF is increasingly being used because of its non-inferior antiviral properties, lower risk of nephrotoxicity, and lower decrease in bone mineral density than TDF. There is growing evidence of unfavorable effects of TAF on weight and body mass index (BMI) in antiretroviral therapy (ART)-experienced patients treated with TAF-based ART. The aim of this study was to evaluate whether switching from TDF-containing to TAF-containing ART is associated with an increase in BMI and body weight in ART-experienced patients. Two study groups were established: 32 patients who switched from TDF to TAF only and 68 patients who switched from TDF to TAF along with changes to other components of the ART regimen. Significant weight gain and BMI increase was observed during the first year after initiation of TAF-containing ART regimens in both groups (mean change +1.91 kg and +0.61 kg/m2 in the first group and +1.50 kg and +0.49 kg/m2 in the second group). During the second year of TAF-based treatment, a sustained trend of body weight and BMI increase was noted only in the second group (mean change +1.46 kg, + 0.46 kg/m2). Analysis of body weight changes in certain subpopulations from the second group (selected based on patients’ baseline characteristics) revealed a significant weight gain within two years after the switch in patients over 50 years old and in those whose ART had lasted longer than 10 years. These findings suggest that a possible impact of TAF on weight gain should be taken into account when selecting ART components, especially in older patients or those with a long history of antiretroviral treatment.

Abstract #534 Influence of Gestational Weight Gain and Pre-Pregnancy Body Mass Index on Birth Weight

2019 ◽  
Vol 25 ◽  
pp. 268-269
Author(s):  
Bolanle Okunowo ◽  
Ifedayo Odeniyi ◽  
Oluwarotimi Olopade ◽  
Olufemi Fasanmade ◽  
Omololu Adegbola ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Weight Gain ◽  
Birth Weight ◽  
Gestational Weight Gain ◽  
Body Mass ◽  
Gestational Weight

Disentangling the obesity paradox in upper gastrointestinal cancers: Weight loss matters more than body mass index

2021 ◽  
Vol 72 ◽  
pp. 101912
Author(s):  
Shria Kumar ◽  
Nadim Mahmud ◽  
David S. Goldberg ◽  
Jashodeep Datta ◽  
David E. Kaplan
Keyword(s):  
Body Mass Index ◽  
Weight Loss ◽  
Body Mass ◽  
Obesity Paradox ◽  
Gastrointestinal Cancers ◽  
Upper Gastrointestinal

Enrolling Caregivers in Obesity Interventions to Improve Obesity-Related Outcomes in Children

2021 ◽  
pp. 019394592110370
Author(s):  
Hannah Bessette ◽  
MinKyoung Song ◽  
Karen S. Lyons ◽  
Sydnee Stoyles ◽  
Christopher S. Lee ◽  
...  
Keyword(s):  
Physical Activity ◽  
Body Mass Index ◽  
Weight Loss ◽  
Linear Regression ◽  
Body Mass ◽  
Sedentary Time ◽  
Vigorous Physical Activity ◽  
Weight Loss Program ◽  
Weight Loss Programs ◽  
Obesity Interventions

In this study, we assessed the influences of change in moderate-to-vigorous physical activity (MVPA)/sedentary time (ST) of caregivers participating in a commercial weight-loss program on their children’s change in MVPA/ST. Data from 29 caregivers and their children were collected over 8 weeks. We used multivariable linear regression to assess associations of changes in caregiver’s percent of time spent in MVPA/ST and changes in their child’s percent of time spent in MVPA/ST. For caregivers that decreased body mass index (BMI) over 8 weeks, changes in caregivers’ MVPA was strongly associated with the change in children’s MVPA (β = 2.61 [95% CI: 0.45, 4.77]) compared to caregivers who maintained/increased BMI (β = 0.24 [–2.16, 2.64]). Changes in caregivers’ ST was strongly associated with changes in children’s ST (β = 2.42 [1.02, 3.81]) compared to caregivers who maintained/increased BMI (β = 0.35 [–0.45, 1.14]). Findings reinforce encouraging caregivers to enroll in weight-loss programs for the benefit of their children as well as for themselves.

Sign in / Sign up

Export Citation Format

Share Document